(4-bromopyrazolo[1,5-a]pyridin-3-yl)methanol | 1356144-50-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡唑并吡啶类
• 英文名称: (4-bromopyrazolo[1,5-a]pyridin-3-yl)methanol
• 英文别名: (4-Bromopyrazolo[1,5-a]pyridin-3-yl)methanol
• CAS: 1356144-50-7
• 化学式: C₈H₇BrN₂O
• 分子量: 227.06
• InChiKey: JBJANJPMDOHXGK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.9
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  37.5
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  (4-bromopyrazolo[1,5-a]pyridin-3-yl)methanol 在 manganese(IV) oxide 作用下， 以 二氯甲烷 为溶剂， 反应 96.0h， 以89%的产率得到4-bromopyrazolo[1,5-a]pyridine-3-carbaldehyde
  参考文献：
  名称：

  Discovery of pyrazolo[1,5-a]pyridines as p110α-selective PI3 kinase inhibitors

  摘要：

  We have made a novel series of pyrazolo[1,5-a]pyridines as PI3 kinase inhibitors, and demonstrated their selectivity for the p110 alpha isoform over the other Class Ia PI3 kinases. We investigated the SAR around the pyrazolo[1,5-a] pyridine ring system, and found compound 5x to be a particularly potent example (p110 alpha IC50 0.9 nM). This compound inhibits cell proliferation and phosphorylation of Akt/PKB, a downstream marker of PI3 kinase activity, and showed in vivo activity in an HCT-116 human xenograft model. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2011.11.029
• 作为产物：
  描述：

  6-溴吡唑并[1,5-A]吡啶-3-甲酸 在 sodium tetrahydroborate 、 水 作用下， 以 四氢呋喃 为溶剂， 反应 18.5h， 生成 (4-bromopyrazolo[1,5-a]pyridin-3-yl)methanol
  参考文献：
  名称：

  [EN] INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF
  [FR] INHIBITEURS DE CYSTÉINE PROTÉASES ET LEURS MÉTHODES D'UTILISATION

  摘要：

  The disclosure provides compounds with nitrile warheads and their use in treating medical diseases or disorders, such as viral infections. Pharmaceutical compositions and methods of making various compounds with nitrile warheads are provided. The compounds are contemplated to inhibit proteases, such as the 3C, CL- or 3CL-like protease.

  公开号：

  WO2023044171A1

文献信息

• 10.1016/j.tet.2024.134020
  作者：Ohki, Hugo、Komatsuda, Masaaki、Kondo, Hiroki、Yamaguchi, Junichiro

  DOI：10.1016/j.tet.2024.134020

  日期：——

  We have developed a novel ring-opening difluorination process for pyrazoloazines. Utilizing 2.5 equivalents of Selectfluor®, this method enables electrophilic difluorination and subsequent ring-opening of pyrazoloazines, yielding the corresponding difluoroalkylated azines. Additionally, our protocol extends to the decarbonylative difluorination of pyrazoloazines when starting with a formyl group at

  我们开发了一种新型的吡唑并嗪开环二氟化工艺。该方法利用 2.5 当量的 Selectflu®，实现亲电二氟化和随后吡唑并嗪的开环，产生相应的二氟烷基化吖嗪。此外，我们的方案还扩展到以 C3 位甲酰基为起始的吡唑并嗪的脱羰二氟化，证明了该方法的多功能性和广泛适用性。二氟化化学的这一进步为二氟化化合物的合成提供了一条新途径，可能丰富药物化学和材料科学从业者的工具包。
• [EN] INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF<br/>[FR] INHIBITEURS DE CYSTÉINE PROTÉASES ET LEURS MÉTHODES D'UTILISATION
  申请人：[en]PARDES BIOSCIENCES, INC.

  公开号：WO2023044171A1

  公开（公告）日：2023-03-23

  The disclosure provides compounds with nitrile warheads and their use in treating medical diseases or disorders, such as viral infections. Pharmaceutical compositions and methods of making various compounds with nitrile warheads are provided. The compounds are contemplated to inhibit proteases, such as the 3C, CL- or 3CL-like protease.
• Discovery of pyrazolo[1,5-a]pyridines as p110α-selective PI3 kinase inhibitors
  作者：Jackie D. Kendall、Patrick D. O’Connor、Andrew J. Marshall、Raphaël Frédérick、Elaine S. Marshall、Claire L. Lill、Woo-Jeong Lee、Sharada Kolekar、Mindy Chao、Alisha Malik、Shuqiao Yu、Claire Chaussade、Christina Buchanan、Gordon W. Rewcastle、Bruce C. Baguley、Jack U. Flanagan、Stephen M.F. Jamieson、William A. Denny、Peter R. Shepherd

  DOI：10.1016/j.bmc.2011.11.029

  日期：2012.1

  We have made a novel series of pyrazolo[1,5-a]pyridines as PI3 kinase inhibitors, and demonstrated their selectivity for the p110 alpha isoform over the other Class Ia PI3 kinases. We investigated the SAR around the pyrazolo[1,5-a] pyridine ring system, and found compound 5x to be a particularly potent example (p110 alpha IC50 0.9 nM). This compound inhibits cell proliferation and phosphorylation of Akt/PKB, a downstream marker of PI3 kinase activity, and showed in vivo activity in an HCT-116 human xenograft model. (C) 2011 Elsevier Ltd. All rights reserved.